Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05861674
Study type Interventional
Source Huahui Health
Contact Jiaying Wen
Phone +86-13552466248
Email wenjiaying@hhhbio.com
Status Recruiting
Phase Phase 2
Start date June 16, 2023
Completion date June 30, 2025